San in Medical Technology

Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium

SAN DIEGO, Dec. 14 /PRNewswire/ -- bioTheranostics, a bioMerieux company that discovers, develops and commercializes new molecular diagnostic tests in oncology, reported today findings from three studies using the company's molecular breast cancer assay to predict risk of disease recurrence in ind...

Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium

HUNTINGTON BEACH, California and AMSTERDAM, December 8 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that leading Agendia and the Netherlands Cancer Institute researchers will present data from multiple studies at the 2008 San Antonio Breast Cancer Sympos...

TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients

SAN DIEGO, Dec. 1 /PRNewswire/ -- TargeGen has announced that an oral presentation of preliminary results from a multi-center, US-based clinical trial of TG101348 in myeloproliferative disease patients has been scheduled at the 2008 American Society of Hematology (ASH) Meeting. Details o...

Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease

Raptor to Support Phase 2a Clinical Trial at UCSD NOVATO, Calif., July 16 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced the execution of a collaboration agreement (the "Agreement") with the University o...

PG500 Series Presented at the AACR Annual Meeting in San Diego

BRISBANE, Australia, April 14 /PRNewswire-FirstCall/ -- Progen Pharmaceuticals Limited (ASX: PGL) (Nasdaq: PGLA ) announced today that it had presented new data on its patented PG500 series of compounds at the annual American Association for Cancer Research (AACR) meeting being held in San Di...

US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium

SAN ANTONIO, Dec. 17 /PRNewswire/ -- A leading cancer physician and researcher affiliated with US Oncology Research, an established community-based research network specializing in Phase I - Phase IV cancer clinical trials, presented findings on a Phase II trial conducted to increase pathologi...

PTC Therapeutics Presents Encouraging Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 30th Annual San Antonio Breast Cancer Symposium

- Company Initiates Phase1b/2 Clinical Trial in Breast Cancer - SAN ANTONIO and SOUTH PLAINFIELD, N.J., Dec. 17 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule drugs targeting post-tran...

Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R)

Presentations Provide New Insights into Treatment Impact, Node-Positive Breast Cancer, Measuring ER/PR Scores REDWOOD CITY, Calif., Dec. 17 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX ) today announced results from multiple studies reinforcing the clinical uti...

HERmark(TM) Assay Results in Metastatic Breast Cancer Presented at the San Antonio Breast Cancer Symposium

HER2 Homodimer and HER2 Total Protein Assays Validated in CLIA Laboratory SOUTH SAN FRANCISCO, Dec. 14 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM ) today presented the results of a study detailing the HERmark(TM) Assay's ability to identify metastatic breast cancer pati...

Monogram Announces Posters to be Presented at the 30th San Antonio Breast Cancer Symposium

Scientific Presentations Detail Progress with VeraTag(TM) Assays in Breast Cancer SOUTH SAN FRANCISCO, Calif., Dec. 10 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM ) today announced five posters to be presented at the 30th San Antonio Breas...

Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium

REDWOOD CITY, Calif., Dec. 7 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX ) today announced that results from eight studies of the company's Oncotype DX(R) breast cancer test are scheduled to be presented at the 30th Annual San Antonio Breast Cancer Symposium, taking place Dec...

Tezampanel, TorreyPines Therapeutics' Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego

Data Suggest Potential for Treating Motor System Disorders LA JOLLA, Calif., Oct. 17 /PRNewswire/-- Tezampanel, a novel small molecule currently in clinical development by TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) for the treatment of acute migraine headache, was shown in an indep...

Vaxiion Researchers Discover Novel Vaccine Delivery System in Collaboration with San Diego State University

SAN DIEGO--(BUSINESS WIRE)--Mar 8, 2007 - Vaxiion Therapeutics, Inc. today announced that its researchers, in collaboration with San Diego State University, have discovered a 'minicell' vaccine delivery system that has potential to protect against several disease-causing infections. These findings...

Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA

... LYON, France and SWIFTWATER, Pa., Aug. 7 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: san and NYSE: SNY ), announced today the company has submitted to the U.S. Food and Drug Administration (FDA) a supplemental application for licensure o...

Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership

...needs, we are looking to expand both the targets and the realm of possible treatments that can benefit people living with diabetes." Based in san Diego, GNF was founded in 1999. Funded by the Novartis Research Foundation, its mission is to develop and apply innovative technologies to the discove...

Nektar Therapeutics Reports Second Quarter 2009 Financial Results

... san CARLOS, Calif., Aug. 4 /PRNewswire-FirstCall/ -- N...or neutropenia. Nektar is headquartered in san Carlos, California, with additional R&D operat...peutics 650-631-4954 Susan Noonan The san Group 212-966-3650 ...

Study Shows Brain Fitness can Save Medicare Billions

... san FRANCISCO, Aug. 4 /PRNewswire/ -- Just ten hours of the right brain fitness exercises can have a significant and long lasting impact on healthcare...

Scientists Discover Origin of Malaria

... Discovery Could Lead to Development of New Treatments, Prevent Future Plagues san FRANCISCO, Aug. 3 /PRNewswire-USNewswire/ -- Today scientists reported that they have discovered the origin of malaria, one of the deadliest diseases ...

Treatment Shows Excellent Results for Providence Tarzana Patients Following Cardiac Arrest

...: Providence Saint Joseph, Providence Holy Cross, Providence Tarzana, Providence Little Company of Mary Torrance and Providence Little Company of Mary san Pedro Medical Centers. Providence Health is a nonprofit Catholic organization dedicated to quality, compassionate care for all and to investing in the...

Unlikely Treatment Identified by BrainCells Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering From Depression

... san DIEGO, July 27 /PRNewswire/ -- BrainCells Inc., a company leading the scientific research of neurogenesis using its proprietary platform technology ...

NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study

... san MATEO, Calif., July 24 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX ) announced today the preliminary results of a short-term clinical st...

R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent

... SOUTH san FRANCISCO, Calif., July 23 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that in the TASKi3 Phase 2b clinica...

Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing

... SOUTH san FRANCISCO, Calif., July 21 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on innovativ...

UPDATE: US Oncology Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201

...launching the Phase 3 clinical trial so rapidly after the close of the Phase 2 trial," said Barry Sherman, M.D., head of clinical development at South san Francisco-based BiPar Sciences, which is developing BSI-201. BiPar is a wholly owned subsidiary of Paris-based sanofi-aventis. "Our primary focus now ...

Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study

... san DIEGO, INDIANAPOLIS and CAMBRIDGE, Mass., July 20 /PRNewswire-FirstCall/ --...tential therapies to treat diabetes and obesity. Amylin is headquartered in san Diego, California. Through a long-standing commitment to diabetes...

Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results

... san DIEGO, July 17 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX ), a biopharmaceutical company focused on the treatment of obe...

University of Michigan Study Shows SEQUENOM's MassARRAY Technology Identifies HPV Infections Missed by Standard Hybridization Test

... san DIEGO and ANN ARBOR, Mich., July 13 /PRNewswire-FirstCall/ -- Results from ...nd other disorders. The company was founded in 1994 and is headquartered in san Diego, California. For more information please visit http://www.sequenom...

Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharma's Product Class

... san DIEGO, July 13 /PRNewswire/ -- Research published in the June 26, 2009 edition of Proceedings of National Academy of Sciences provides further evide...

PTSD Associated With Higher Alzheimer's/Dementia Risk; Moderate Alcohol Consumption May Lower it

... Research for the Department of Psychiatry at the University of California, san Francisco, and Chief of Geriatric Psychiatry and Director of the Memory Disorders Clinic at the san Francisco VA Medical Center, and colleagues sought to determine if PTSD is ...

First Patient of NOTES Investigational Device Exemption (IDE) Study Successfully Treated With Ethicon Endo-Surgery Devices

...variables. The other three sites participating in the trial include Northwestern University Feinberg School of Medicine; University of California - san Diego Medical Center; and the University of Missouri University Hospital. "The success of the first case of the IDE study and the associated d...

Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial

... SOUTH san FRANCISCO, Calif., July 9 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that R788 (fostamatinib disodium) pr...

Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis

... SOUTH san FRANCISCO, Calif., July 8 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that the Company plans to host a con...

Why Do African-Americans Fare Worse With Cancer? Access and Economics Are Only Part of the Story

...d cancer centers. The Group is headquartered at the University of Michigan in Ann Arbor , Mich. (734-998-7140). The Group has an operations office in san Antonio, Texas and a statistical center in Seattle, Wash. ...

5-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH

... BRIDGEWATER, N.J., July 6 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: san and NYSE: SNY ) announced today that the results of the long-term, 5-year study of Lantus(R) (insulin glargine [rDNA] injection) versus NPH insulin ...

Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled

... san DIEGO, June 30 /PRNewswire/ -- Accumetrics, Inc. announces that it has reached the halfway mark (1,600 patients) in the enrollment of its landmark cli...

Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients with Complicated Urinary Tract Infections

... san DIEGO, June 30 /PRNewswire/ -- Calixa Therapeutics...tics, which is privately held, is headquartered in san Diego and has operations in the san Francisco Bay Area. For additional information, p...

Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications

... aTyr Pharma Targets for Novel Biotherapeutics Based On Naturally Resected tRNA Synthetases san DIEGO, June 29 /PRNewswire/ -- Pangu BioPharma, a subsidiary of aTyr Pharma in Hong Kong, today announced the filing of its third patent application o...

Sanofi-aventis Stands Behind the Safety of Lantus(R)

... BRIDGEWATER, N.J., June 26 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: san and NYSE: SNY ) has just been made aware of data associated with a retrospective follow-up of four patient registries. The results of these data cle...

Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints

...e, Division of Clinical Immunology and Rheumatology, and Director, University Clinical Research Center, University of Texas Health Science Center at san Antonio. "Sodium oxybate has shown a positive effect on a number of the symptoms of fibromyalgia, and thus could have a significant impact on patients...

Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis

... san DIEGO, June 24 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the initiation of a second Phase 2 clinical trial with a novel drug candid...